His main research concerns Prostate cancer, Surgery, Internal medicine, Cancer and Oncology. Robert Huddart combines subjects such as Radiation therapy, Depression and Anxiety with his study of Prostate cancer. His work deals with themes such as Hazard ratio and Urology, which intersect with Surgery.
His Cancer research incorporates elements of Single-nucleotide polymorphism, Genome-wide association study, Side effect and Gynecology. The study incorporates disciplines such as Genotyping and Case-control study in addition to Single-nucleotide polymorphism. In his research on the topic of Oncology, Prostatectomy is strongly related with Pathology.
His primary areas of investigation include Internal medicine, Oncology, Radiation therapy, Surgery and Chemotherapy. Prostate cancer, Testicular cancer, Cancer and Clinical endpoint are the primary areas of interest in his Internal medicine study. As a member of one scientific family, Robert Huddart mostly works in the field of Prostate cancer, focusing on Single-nucleotide polymorphism and, on occasion, Genotyping.
His Oncology study combines topics in areas such as Germ cell tumors, Pathology and Germ cell. His Radiation therapy research includes elements of Bladder cancer, Toxicity, Randomized controlled trial and Nuclear medicine. His work carried out in the field of Surgery brings together such families of science as Hazard ratio, Clinical trial and Urology.
His primary scientific interests are in Internal medicine, Oncology, Radiation therapy, Radiology and Bladder cancer. His Oncology study integrates concerns from other disciplines, such as Genome-wide association study, Regimen, Germ cell cancer, Germ cell and Locally advanced. His Radiation therapy research integrates issues from Clinical endpoint, Magnetic resonance imaging, General surgery, Hazard ratio and Cystectomy.
His studies in Radiology integrate themes in fields like Standard treatment, Seminoma and Prostate cancer. His Prostate cancer study improves the overall literature in Cancer. His studies deal with areas such as Biomarker, Concomitant, Randomized controlled trial and Adaptive radiotherapy as well as Bladder cancer.
His scientific interests lie mostly in Radiation therapy, Internal medicine, Bladder cancer, Clinical endpoint and Oncology. The concepts of his Radiation therapy study are interwoven with issues in Magnetic resonance imaging and Quality of life. Dose fractionation, Cohort study and Absolute risk reduction are among the areas of Internal medicine where the researcher is concentrating his efforts.
His Bladder cancer research incorporates themes from Lower risk, Randomized controlled trial, Rectum and Chemoradiotherapy. His research integrates issues of Muscle invasive, Locally advanced, Chemotherapy, Prospective cohort study and Germ cell cancer in his study of Oncology. His study looks at the intersection of Radiology and topics like Cohort with Toxicity, Prostate cancer and Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird.
Lancet Oncology (2007)
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A Eeles;Rosalind A Eeles;Zsofia Kote-Jarai;Graham G Giles;Graham G Giles;Ali Amin Al Olama.
Nature Genetics (2008)
Radiotherapy with or without Chemotherapy in muscle-invasive bladder cancer
Nicholas D. James;Syed A. Hussain;Peter Jenkins;Jean Tremlett.
The New England Journal of Medicine (2012)
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers.
European Urology (2008)
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
H. J. Schmoll;R. Souchon;S. Krege;P. Albers.
Annals of Oncology (2004)
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
R.A. Huddart;A. Norman;M. Shahidi;A. Horwich.
Journal of Clinical Oncology (2003)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Rosalind A. Eeles;Ali Amin Al Olama;Sara Benlloch;Edward J. Saunders.
Nature Genetics (2013)
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
Rosalind A. Eeles;Zsofia Kote-Jarai;Ali Amin Al Olama;Graham G. Giles;Graham G. Giles.
Nature Genetics (2009)
Testicular germ-cell cancer
Alan Horwich;Janet Shipley;Robert Huddart.
The Lancet (2006)
Stereotactic body radiotherapy for oligometastases.
Alison C Tree;Vincent S Khoo;Rosalind A Eeles;Merina Ahmed.
Lancet Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: